View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 4, 2016updated 02 Dec 2021 12:01pm

Eisai launches Uritos tablets to treat overactive bladder in Thailand

Pharmaceutical company Eisai has launched Uritos tablets (imidafenacin) to treat overactive bladder (OAB), in Thailand.

O ffice.jpg” alt=”” />

Pharmaceutical company Eisai has launched Uritos tablets (imidafenacin) to treat overactive bladder (O AB), in Thailand.

O AB is a urological condition, where the patient will have a frequent, sudden urge to urinate. It is often accompanied by frequent urination and nocturia, and in some cases by urge urinary incontinence.

Kyorin Pharmaceutical , a O RIN-Holdings-Inc/”>subsidiary of Kyorin Holdings, has given Eisai the exclusive rights to develop and market the therapeutic agent in China, India, Sri Lanka and ASEAN countries in 2009.

Uritos is an anti-cholinergic agent that exhibits selective antagonistic effects on M3 and M1 muscarinic subtype receptors to help alleviate the urge to urinate, frequent urination and urge urinary incontinence associated with O AB, Eisai said in a statement.

The most common side effects associated with the consumption of Uritos are thirst and constipation.

“According to the clinical guidelines for overactive bladder in Japan, the prevalence of O AB in the country ranges from 5% to 20%.”

Previous studies have shown that people suffering from brain or spinal cord related diseases such as stroke or Parkinson’s disease, as well as enlargement of the prostate are at high risk of O AB.

According to the clinical guidelines for overactive bladder in Japan, the prevalence of O AB in the country ranges from 5% to 20%.

Although the prevalence of O AB in Asia is unknown, reports suggest that 29.9% of men and 34.7% of women older than 18 experienced some symptoms of O AB, many of whom did not receive appropriate treatment due to lack of disease awareness.

In a separate development, Eisai’s research subsidiary Morphotek has signed an exclusive licensing agreement with Eurofarma Laboratórios to develop and commercialise the monoclonal antibody farletuzumab as a potential anticancer agent in Latin America.


Image: Eisai head office in Tokyo. Photo: courtesy of KW.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology